TREATMENT-RESISTANT SCHIZOPHRENIA DISCUSSION UPON A CASE REPORT
|
|
- Holly Rodgers
- 6 years ago
- Views:
Transcription
1 CAZ CLINIC TREATMENT-RESISTANT SCHIZOPHRENIA DISCUSSION UPON A CASE REPORT Laura Ghebaur*, Claudia Damian**, Laura Plãviþu**, Dan Prelipceanu**** Rezumat: 20% dintre pacienþii cu schizofrenie rãmân rezistenþi la tratamentul cu neuroleptic ºi continuã sã pre - zinte idei delirante, halucinaþii ºi tulburãri formale de gândire. Eºecul de a rãspunde la douã antipsihotice administrate în doze obiºnuite este predictiv pentru un rãspuns neadecvat la o altã medicaþie neurolepticã (alta decât clozapina). Rezistenþa la tratament în contextul clinic implicã persistenþa simptomelor pozitive mai mult de trei luni în ciuda aderenþei la medicaþia adecvatã. Strategiile de tratament actuale includ schimbarea antipsihoticului, administrarea unei doze mari de neuroleptic atipic, iniþierea unui trial cu clozapinã, potenþarea clozapinei sau a altui antipsihotic atipic si terapia cognitiv-comportamentalã. Cuvinte cheie: schizofrenie, rezistenþã la tratament, strategii terapeutice, combinaþia de antipsihotice. Abstract: About 20% of patients with schizophrenia remain «treatment-resistant» to the antipsychotic effects of neuroleptic therapy and continue to manifest delusions, hallucinations as well as formal thought disorder. It was shown that failure to respond to two antipsychotics at usual doses is predictive of an inadequate response to further nonclozapine medication. Treatment resistance in the usual clinical context implies persistent positive symptoms despite adherence with adequate medication for greater than 3 months. Current treatment strategies include switching antipsychotic agents, a trial of a high-dose atypical antipsychotic, initiation of a trial of clozapine, augmentation of clozapine or another atypical antipsychotic agent and cognitive-behavioral therapy. Key words: schizophrenia, treatment resistance, therapeutic strategies, combination of antipsychotics. INTRODUCTION Psychopharmacologic treatment can suppress psychotic symptoms in most patients with schizophrenia. 10% to30% of patients have little or no response to antipsychotic medications and up to an additional 30% of patients have only partial responses to treatment (1). The concept of nonresponse to treatment is multidimensional, as no response may be present in positive, negative, cognitive, or depressive symptom domains (2). Even if a patient s positive symptoms respond or remit with an antipsychotic agent, residual negative and cognitive symptoms often persist (1). There are several general principles for the treatment of refractory schizophrenia. When encountered by what appears to be treatment resistance, the clinician should review the diagnosis, check for psychiatric or substance abuse comorbidity, rule out medical comorbidities, and assess the adequacy of past and present pharmacotherapy (duration / dosage / compliance). Unfortunately, such data gathering is often made difficult due to poor history from the patient and a fragmented system leading to difficulty accessing medical records. Treatment resistance may be related to suboptimal dosing of the antipsychotic, nonadherence with the prescribed medication regimen, ineffectiveness of the antipsychotic, or substance abuse (1). Once treatment resistance is established, the clinician should identify areas of nonresponse; develop a sequential, systematic treatment plan; determine the length of each trial; define outcome criteria; and use a standardized rating scale to monitor response (eg, Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale). The clinician should consider that inadequate psychosocial treatment may create the appearance of treatment resistance (3). Treatment-resistant schizophrenia can be defined based on little or no symptomatic response to multiple (at least 2) antipsychotic trials of an adequate duration (at least 6 weeks) and at a therapeutic dose range.(1) To open up thinking about treatment at this point in the illness, some psychiatrists have argued for replacing the term treatment resistance with incomplete recovery (2). CLINICAL CASE REPORT The patient IG, aged 48 years old, is hospitalized for visual complex figurative hallucinations and permanent complex commenting and imperative auditory hal- * medic rezident an V, Spitalul Clinic de Psihiatrie Al. Obregia Bucuresti ** medic rezident an I, Spitalul Clinic de Psihiatrie Al. Obregia Bucuresti *** prof. dr., sef Catedra Psihiatrie UMF Carol Davila Bucuresti, Spitalul Clinic de Psihiatrie Al. Obregia Bucuresti 53
2 Laura Ghebaur ºi colab.: Treatment-resistant schizophrenia - discussion upon a case report lucinations, hallucinating behavior, psychomotor restlessness, sleep disorder, major social and occupational dysfunction. From collateral relative antecedents it can be mentioned that patient s brother is suffering from epilepsy. The onset of the psychiatric disorder was at 34 years old, apparently unexpectedly, with visual zoopsical hallucinations and auditory hallucinations, symptomatology recovered with conventional antipsychotic (haloperidol) and anxiolytic-sedative treatment (diazepam). Since that time, the patient had yearly hospitalizations for psychotic recurrences with full interepisodic recovery. From longitudinal symptomatologic course of the disease it results that the patient presented thought disorders: persecutory and reference delusions, external influence ideation (mental automatism Kandinski- Clerambault). Since 2001 perceptible productivity phenomenon had become permanent and hallucinating behavior had been installed. This psychopathological description caused clinically significant impairment in important areas of functioning, so that in 2002 the patient had retired from his activity. The patient has a relationship with a person having a pathological condition from the same spectrum. Along the course of the disease there have been given conventional and atypical antipsychotics: haloperidol, flupentixol, quetiapine, risperidone, aripiprazole, olanzapine, clozapine, duration of successful treatment being of several months. Mental Status examination: The patient is dressed slatternly, with unsuitable hygiene, consciously, able to co-operate, hypomobile mimicry, paucity of expressive gestures. Unchanging facial expression. Lack of vocal inflections. Psychic contact easy to establish and maintain, poor visual contact; he is avoiding eye-to-eye contact, is looking downwards. Oriented to person, time and place. Reduced capacity to concentrate his attention. Social inattentiveness. Complex visual and auditory hallucinations with aggressive content. Impaired learning of new material and reduced ability to recall past experiences. Slowing down of ideational rhythm, ideative flood focused on automatisms of Kandinski- Clerambault type. Impaired insight. Logical associations possible, ideative coherence still kept. Poverty of speech. Anxious mood. Affective flatttening. Sleeplessness at awakening. Food appetite undisturbed. Hallucinating behavior. Psychomotor restlessness. Clinically significant social and occupational dysfunction.(he is able to do some useful activities). Relatively well preserved personality. Cerebral CT scanning: Without supra- or infratentorial heterodense lesions visible at the native examination. Symmetrical ventricular system, with normal size. Slight thickening of the mucous membrane of jaw sinus, right ethmoidal cells and sphenoidal sinus. Positive diagnosis: Paranoid schizophrenia Differential diagnosis: 1. Other schizophrenia subtypes: undifferentiated schizophrenia, catatonic schizophrenia. 2. Psychotic Disorder due to a General Medical Condition; 3. Substance-Induced Psychotic Disorder; 4. Schizoaffective disorder; 5. Delusional Disorder; 6. Mood disorder with psychotic features; 7. Schizotypal Personality Disorder; 8. Schizoid Personality Disorder; 9.Paranoid Personality Disorder. Course and prognosis: Natural course of the disease: ondulatory (exacerbations and remissions) towards deterioration. Factors of good prognosis: acute onset in adulthood, paranoid subtype of schizophrenia, good compliance with treatment. Factors of poor outcome: perceptual disturbances resistant to many pharmacologic treatment strategies; loss of work capacity, social abilities significantly impaired. Treatment: consisted of pharmacologic and psychosocial approach. Long-term strategy should aim adequate antipsychotic treatment and the broadening of social support and care offered in difficult life situations. In our clinic, we have been given to the patient a combination of atypical neuroleptics : olanzapine 30mg /day and amisulpride 800mg/day with favourable evolution (reduced intensity of positive symptoms). Specific features of the case: personality preservation to a certain extent, relatively well preserved cognitive processes, with incomplete affected emotionalvolitional capacity. DISCUSSION Taking into consideration the specific features of the case presented we initially thought of reviewing the diagnosis. The possibility of having to do with a paraphrenia was based on Kraepelin s definition from1909, once this nosological entity has been delimited from systematized delusions frame: «that endogenous psychosis characterized by a chronic systematized hallucinating delusion with fantastical nature, whose imaginative abundance, going almost to setting up a fantastical world, is contrasting with the long preservation of a behavior and an emotional life relatively corresponding to reality» (4). A classification proposed by H.Ey and other authors settles thus the nosological position of chronic systematized delusions(4): 1) Cuvintul "assertive" din limba engleza a fost trades de autor cu "afirmativ" si in text sunt folosit alternativ, ambele cuvinte, "afirmativ" si "asertiv" pentru ca autorul nu considera satisfacator echivalentul gasit. 54
3 Revista Românã de Psihiatrie, seria a III-a, vol. X, nr. 1-2, 2008 A. Without poor outcome: Chronic systematized delusional and hallucinating psychosis (paraphrenia). Other chronic hallucinating psychosis. Chronic delusional nonhallucinating psychosis (paranoia). B. With dissociative course: Schizophrenia-paranoid subtypes. It is possible that one subtype advances into another subtype, but also to be fixed in a certain type. Within the framework of chronic delusional disorders we can speak about species of the same kind, not about different kinds. Looking at the unity of delusional disorders of personality in dynamic perspective, some authors concluded that the pathological process is unfolding in different stages. Thus they have differentiated paranoic, paraphrenic and schizophrenic stages (4). Durations for therapeutic success of anterior antipsychotic treatments are in concordance with the latest data literature. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), initiated by the National Institute of Mental Health in U.S.A., is a study involving comparison of four second generation antipsychotics (olanzapine, quetiapine, risperidone and ziprasidone) and one first generation antipsychotic (perphenazine) for the treatment of schizophrenia under double-blind randomized conditions (Lieberman et al., 2005). The primary outcome of the study was to assess the effectiveness of the different treatments. Effectiveness was conceptualized as a combination of efficacy and tolerability. The study duration was planned for 18 months in the first phase with a doubleblind condition of treatment. After discontinuation from the first phase, patients could be assigned for other treatments in phases 2 and 3. An analysis of the «duration of successful treatment» is among many considerable results of the study. The comparisons using this parameter revealed significant differences between olanzapine vs quetiapine (p<0,001), riperidone (p=0,002) and perphenazine (p=0,013), and for risperidone vs. quetiapine (p=0,021). In absolute number, the duration of successful treatment was 3 months (2-5 months) for olanzapine; in all other groups, the duration of successful treatment ranges 0-1 or 0-2 months (5). Clozapine remains the gold standard of treatment for schizophrenic patients with treatment-resistant symptoms. However, a considerable number of patients treated with clozapine are still nonresponsive or only partially responsive. The combined application of antipsychotic drugs is an established step in the cascade of treatment strategies of treatment-resistant schizophrenia (6, 7). Use of antipsychotic polypharmacy is still controversial, but occurs frequently within clinical practice, with rates ranging from 5% to 18% in outpatients and up to 50% or even more in inpatients (8, 9). These polypharmacy usage patterns are in contrast with most published treatment guidelines (10, 11) and should be limited to severe cases and only if monotherapy with different classes of first- or second-generation antipsychotics in sufficient doses over an adequate time period have proven ineffective. It is increasingly acknowledged that the time taken to respond to clozapine for some individuals may be up to or beyond 1 year. In particular, time to response may be longer for patients with past episodes, as each successive episode may increase the time to remission. In light of these findings, combination therapies involving clozapine should be considered only if the treatment duration with clozapine monotherapy was 6 12 months. There are four double-blind, placebo-controlled studies of combinations of clozapine and other antipsychotic drugs in the literature (12), but most investigations have been conducted with an open uncontrolled design and have included only a small series of patients. Risperidone is the most extensively documented clozapine augmentation agent. A double-blind study (12) and two uncontrolled prospective studies (13) reported improvement with the combination, with no significant increase in adverse effects. In contrast, a double-blind study and an uncontrolled prospective trial reported no benefit. The combination of sulpiride or amisulpride, which are relatively selective D2 antagonists, and clozapine has shown promising effects in different studies (14, 15). In all of these studies, the investigators reported a significant benefit in terms of improvement of psychopathological state and adverse effects. Furthermore, daily clozapine doses could be reduced and lower individual drug doses could be used in combination therapy compared with monotherapy. Other investigators have reported on the combination of ziprasidone and clozapine, amisulpride and olanzapine, risperidone and amisulpride, and ziprasidone and amisulpride (16, 17). A clinical observation conducted by Ziegenbein M, Wittmann G and Kropp S, in 2005, tested the efficacy of the combination between aripiprazole 15-35mg/day and clozapine mg/day at eleven patients with treatment-resistant schizophrenia. Patients had to have remained on a stable dose of clozapine for at least 6 months in order to ensure a reasonable opportunity to respond to clozapine monotherapy. Clinical status was evaluated at baseline and at 3 months follow-up using the Brief Psychiatric Rating Scale (BPRS). Treatment response was defined as a reduction in total BPRS score of =20%. All patients completed 3 months combination treatment. There was a significant reduction in the mean BPRS score in seven patients (63.6%) over the 3 months of combination treatment. Augmentation with aripiprazole in clozapine-treated patients did not result in a corresponding increase in adverse effects. Use of the combination allowed a significant reduction in the daily dose of clozapine. Combined application of cloza- 55
4 Laura Ghebaur ºi colab.: Treatment-resistant schizophrenia - discussion upon a case report pine and aripiprazole is in accordance with a neurobiological rationale, because aripiprazole has greater affinity for D2 receptors compared with clozapine. The mechanisms underlying the combined action of antipsychotics still remain unclear. Most authors have suggested that the additive pharmacokinetic effect on dopamine D2/D3 receptors might be the most important synergistic mechanism to explain the favourable therapeutic outcome of combination strategies (18). Some authors believe that the efficacy of the combination of atypical antipsychotics and clozapine may be attributable to the synergistic receptor profiles of the two substances, rather than to a pharmacokinetic phenomenon. The stability of serum clozapine levels over the investigation period in some studies suggests that the benefit of the combination strategies of atypical antipsychotics to clozapine is not a consequence of increasing serum clozapine levels, which would constitute a pharmacokinetic interaction. Positron emission tomography (PET) data demonstrate that D2 receptor occupancy of 70% is necessary for therapeutic benefits, while occupancy of >80% is associated with extrapyramidal symptoms (19). The risks of antipsychotic polypharmacy have not been well studied, and information about long-term risks is particularly sparse. In terms of augmentation with mood stabilizers, there have been described only 2 double-blind studies. The first study used lithium, and aimed for a therapeutic lithium level of 0.5 meq/l. Patients with schizoaffective disorder showed improvement in symptoms and cognition compared with patients with schizophrenia, but this combination (clozapine with lithium) is not reccomended in clinical practice. A study with lamotrigine demonstrated improvement in positive symptom severity. Some 21% reported a 3-point decrease in positive symptoms in the lamotrigine group, whereas only 3% showed a 3-point decrease in positive symptoms in the clozapine only group. A controlled study demonstrated the effectiveness of lamotrigine (200mg), gradually added to clozapine, on positive symptomatology and general psychopathology, thus confirming increased glutamatergic neurotransmission hypothesis about positive symptomatology in schizophrenia (20). Lamotrigine, gradually titrated up to 400 mg/day in combination with atypical/conventional antipsychotics, without distinction between different used substances, reduces positive symptomatology and general psychopathology (21). D-serine in dose of 30mg/day can be an adjunct treatment to risperidone and olanzapine, thus reducing negative, positive, cognitive, depressive symptoms in schizophrenia, with a decrease of > 20% on the BPRS total score (22). Sarcosine (glycine transporter inhibitor) is more efficient than NMDA agonists (D-serine, glycine, D- cycloserine) in acute phase of schizophrenia (23). Although pharmacologic treatment is a necessary first step in managing incompletely recovered patients, adjunctive psychosocial interventions are often needed to optimize treatment success. Cognitive-behavioral techniques for schizophrenia have developed over the past few years against a backdrop of skepticism. Yet evidence to support the use of CBT is substantial enough so that many guidelines are recommending it for every patient with schizophrenia, especially those with treatment resistance (24). Most research on CBT in schizophrenia has been conducted using approximately 20 sessions, with each session lasting up to an hour (though sessions can be shorter). To date, more than 20 randomized controlled trials of CBT in schizophrenia have been conducted, indicating a beneficial effect on positive, negative, and depressive symptoms. In CBT, the focus on understanding symptoms helps patients accept and continue medications. Insight is approached systematically, and engagement with the patient is strongly emphasized. There is often a focus on understanding the first episode when positive symptoms initially appeared, so that the patient has to make sense of these experiences. To handle delusions, the therapist gathers information on current beliefs and the links between thoughts, feelings, and behavior. Possible alternatives to the delusional beliefs are explored, investigating and reality testing are encouraged, and the inference chain is gently examined. In addition, the nature of hallucinations is clarified, and the patient is assisted with appropriate attributions, examining the content of hallucinations and exploring coping strategies. Negative symptoms are also targeted, and a focus is on learning to cope with stimulation rather than withdrawing from it. Of course, CBT is not effective for every patient, especially those who are very psychotic, but this treatment strategy can be complementary to pharmacotherapy for many patients. CONCLUSION Current treatment strategies in treatment-resistant schizophrenia include: - switching antipsychotic agents; - a trial of a high-dose atypical antipsychotic; - initiation of a trial of clozapine; - augmentation of clozapine or another atypical antipsychotic agent; - cognitive-behavioral therapy. REFERENCES 1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition, Am J Psychiatry 2004; 161: Pantelis C, Lambert TJR. Managing patients with treatmentresistant schizophrenia. Med J Australia 2003; 178(suppl): S62- S Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50:
5 Revista Românã de Psihiatrie, seria a III-a, vol. X, nr. 1-2, Meiu G. Delirurile cronice sistematizate. In: Predescu V.(ed): Psihiatrie - vol I. Bucureºti, Editura Medicalã,1989, Pecenak J. Relapse prevention in schizophrenia: evidence from long-term, randomized, double-blind clinical trials. In: Jarema M, Sartorius N (eds): Aspects of long-term treatment of psychotic disorders. Society of Integrated Sciences, Neuroendocrinology Letters, Supplement 1, vol 28, 2006, 49: Lerner V, Libov I, Kotler M, et al. Combination of atypical antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder, Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(1): Zink M, Dressing H. Augmentation of Clozapine with atypical antipsychotic substances, Curr Psych Rev 2005; 1: Ananth J, Parameswaran S, Gunatilake S. Antipsychotic polypharmacy, Curr Pharm Des 2004; 10(18): Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation, Curr Med Chem 2004; 11 (3): Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association. Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition, Am J Psychiatry 2004; 161 Suppl. 2: Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update, J Clin Psychiatry 2004; 65(4): Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a radomized, double-blind, placebo-controlled trial, Am J Psychiatry 2005; 162(1): Taylor CG, Flynn SW, Altman S, et al. An open trial of risperidone augmentation of partial response to clozapine, Schizophr Res 2001; 48: Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy, Clin Neuropharmacol 2005; 28(2): Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of Clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004; 110(4): Zink M, Henn FA, Thorne J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004; 19(1): Kaye SK. Ziprasidone augmentation of Clozapine in 11 patients. J Clin Psychiatry 2003; 64(2): Kaempf P, Agelink MW, Naber D. Augmentation of Clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005; 38(1): Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine(d2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157 (4): Tiihanen J, Hallikainen T, Ryynänen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry 2003, 1:54 (11): Kremer I, Vass A, Gorelik I et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry 2004; 56(6): Heresco-Levy U, Javit DC, Ebstein R et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005 Mar 15; 57(6): Lane NY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005, Nov; 62(11): West J. Trends and characteristics of inpatient treatment in routine psychiatric practice in the U.S.. Program and abstracts of the American Psychiatric Association 2005 Annual Meeting; May 21-26, 2005; Atlanta, Georgia. Symposium No48B. 57
Recent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.
Recent Advances in the Antipsychotic Treatment of People with schizophrenia Robert W. Buchanan, M.D. Antipsychotic medications are the primary class of drugs used in the pharmacological treatment of schizophrenia.
More informationSchizophrenia FAHAD ALOSAIMI
Schizophrenia FAHAD ALOSAIMI MBBS, SSC - PSYCH C ONSULTATION LIAISON PSYCHIATRIST K ING SAUD UNIVERSITY Schizophrenia - It is not a single disease but a group of disorders with heterogeneous etiologies.
More informationAPRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1. Harish Arora, Rajdeep Kaur Department of Psychiatry, G.G.S. Medical College, Faridkot, Punjab
APRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1 Original Article An Open Label Study on Amisulpride in Augmentation with Atypical Antipsychotics in Treatment Resistant Patients of Schizophrenia and Schizoaffective
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationSCHIZOPHRENIA SPECTRUM DISORDERS Psychiatry 2 Practical # 2
Psychiatrická klinika LFUK a UNB, Bratislava SCHIZOPHRENIA SPECTRUM DISORDERS Psychiatry 2 Practical # 2 Author: MUDr. Ľubomíra Izáková, PhD. Supervisor: doc. MUDr. Ján Pečeňák, CSc. Podporené grantom
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationEARLY ONSET SCHIZOPHRENIA
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences EARLY ONSET SCHIZOPHRENIA JON MCCLELLAN CHILD STUDY AND TREATMENT CENTER GENERAL DISCLOSURES The University of Washington
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationAre Two Antipsychotics Better Than One?
Are Two Antipsychotics Better Than One? Lauren Hanna, M.D and Delbert Robinson, M.D. Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office
More informationChapter 12. Schizophrenia and Other Psychotic Disorders. PSY 440: Abnormal Psychology. Rick Grieve Western Kentucky University
Chapter 12 Schizophrenia and Other Psychotic Disorders PSY 440: Abnormal Psychology Rick Grieve Western Kentucky University psychotic disorders disorders so severe that the person has essentially lost
More information8/22/2016. Contemporary Psychiatric-Mental Health Nursing Third Edition. Features of Schizophrenia. Features of Schizophrenia (cont'd)
Contemporary Psychiatric-Mental Health Nursing Third Edition CHAPTER 16 Schizophrenia Features of Schizophrenia Prevalence in U.S. is 1.1%. Average onset is late teens to early twenties, but can be as
More informationHandout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes
Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationContemporary Psychiatric-Mental Health Nursing. Features of Schizophrenia. Features of Schizophrenia - continued
Contemporary Psychiatric-Mental Health Nursing Chapter 16 Schizophrenia and Other Psychotic Disorders Features of Schizophrenia Prevalence in U.S. is 1.1%. Average onset is late teens to early twenties,
More information4. General overview Definition
4. General overview 4.1. Definition Schizophrenia is a severe psychotic mental disorder characterized by significant disturbances of mental functioning. It has also been called early dementia, intrapsychic
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psychosis and schizophrenia in children and young people: recognition and management 1.1 Short title Psychosis and schizophrenia
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More informationPsychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com
Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com Introduction Psychotic spectrum disorders include schizotypal personality disorder, delusional disorder, brief psychotic
More informationGoal: To recognize and differentiate different forms of psychopathology that involve disordered thinking and reasoning and distorted perception
Goal: To recognize and differentiate different forms of psychopathology that involve disordered thinking and reasoning and distorted perception Psychotic disorders, or psychoses, are among the most serious
More informationI received help from Bosch Health Care
John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early
More informationEarly Stages of Psychosis. Learning Objectives
Early Stages of Psychosis Stephan Heckers, MD MSc Department of Psychiatry and Behavioral Sciences Vanderbilt University Learning Objectives Summarize the five domains of psychosis Describe how psychotic
More informationWorking with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers
Working with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers Tuesday, February 23, 2016 2pm Eastern Delbert Robinson, M.D. Professor of Psychiatry and Molecular Medicine
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationPsychosis, Mood, and Personality: A Clinical Perspective
Psychosis, Mood, and Personality: A Clinical Perspective John R. Chamberlain, M.D. Assistant Director, Psychiatry and the Law Program Assistant Clinical Professor University of California San Francisco
More information9/3/2014. Contemporary Psychiatric-Mental Health Nursing Third Edition. Features of Schizophrenia. Features of Schizophrenia (cont'd)
Contemporary Psychiatric-Mental Health Nursing Third Edition CHAPTER 16 Schizophrenia Features of Schizophrenia Prevalence in U.S. is 1.1%. Average onset is late teens to early twenties, but can be as
More informationPsychotic Disorders. Schizophrenia. Age Distribution of Onset 2/24/2009. Schizophrenia. Hallmark trait is psychosis
Psychotic Disorders Schizophrenia Schizophrenia Affects people from all walks of life Is about as prevalent as epilepsy Usually begins in late adolescence or early adulthood Hallmark trait is psychosis
More informationIs Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Aristada (Aripiprazole Lauroxil)
More informationPORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016
Appendix 3. Comparison of recommendations from clinical practice guidelines. Data extracted in relation to key health questions that are relevant to a clinician adopting an algorithmic approach to the
More informationBy Jason H. King DECONSTRUCTING THE DSM-5 ASSESSMENT AND DIAGNOSIS OF SCHIZOPHRENIA SPECTRUM DISORDERS THE NEW LANDSCAPE
DECONSTRUCTING THE DSM-5 By Jason H. King ASSESSMENT AND DIAGNOSIS OF SCHIZOPHRENIA SPECTRUM DISORDERS Happy New Year as you engage in your counseling, research, supervision or educational endeavors. I
More informationUpdate on First Psychotic Episodes in Childhood and Adolescence. Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University
Update on First Psychotic Episodes in Childhood and Adolescence Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University Childhood-Onset Psychosis 8% of psychiatrically referred youth
More informationIntroduction. J Mwanza 1, R Paul 1, JM Ncheka 1, P Petlovani 1. 1.University of Zambia School of Medicine, Department of Psychiatry
RESEARCH ARTICLE Appropriateness of antipsychotic drugs prescribed for First episode psychosis by clinicians at Chainama Hills college hospital in Lusaka J Mwanza 1, R Paul 1, JM Ncheka 1, P Petlovani
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationSchizophrenia. Introduction. Overview and Facts
Introduction is a chronic, severe and disabling brain disease that typically shows its first clear symptoms in late adolescence or early adulthood. It is one of several types of Psychotic Disorders. It
More informationTreatment of Children and Adolescents with Schizophrenia
Treatment of Children and Adolescents with Schizophrenia The evidence base pertaining to the pharmacotherapy of schizophrenia in children and adolescents (C&A) is tiny compared to what is available for
More informationCombined Treatment With Amisulpride in Patients With Schizophrenia Discharged From a Short-Term Hospitalization Unit: A 1-Year Retrospective Study
ORIGINAL ARTICLE Combined Treatment With Amisulpride in Patients With Schizophrenia Discharged From a Short-Term Hospitalization Unit: A 1-Year Retrospective Study Juan D. Molina, MD, PhD,* Iván Lerma-Carrillo,
More informationSchizophrenia update for GPs. Prof Douglas Turkington.
Schizophrenia update for GPs. Prof Douglas Turkington.. The Schizophrenias Bleuler vs Kraepelin Sensitivity Disorder Traumatic Psychosis Drug-induced Psychosis Anxiety Psychosis (Kingdon and Turkington,
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationClozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders
Neuropsychobiology 2002;45(suppl 1):37 42 Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders A Case Series B. Hummel S. Dittmann A. Forsthoff N. Matzner
More informationProceedings of the International Conference on RISK MANAGEMENT, ASSESSMENT and MITIGATION
COGNITIVE-BEHAVIOURAL THERAPY EFFICACY IN MAJOR DEPRESSION WITH ASSOCIATED AXIS II RISK FACTOR FOR NEGATIVE PROGNOSIS DANIEL VASILE*, OCTAVIAN VASILIU** *UMF Carol Davila Bucharest, ** Universitary Military
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationAffective Disorders.
Affective Disorders http://www.bristol.ac.uk/medicalschool/hippocrates/psychethics/ Affective Disorders Depression Mania / Hypomania Bipolar mood disorder Recurrent depression Persistent mood disorders
More informationMedication Management. Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015
Medication Management Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015 1 Medication Management Objectives: 1. Principles of psycho-pharmacology
More informationGuidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services
Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care Illinois Department of Children and Family Services Introduction With few exceptions, children and adolescents in
More informationAggression (Severe) in Children under Age 6
ggression (Severe) in Children under ge 6 Level 0 Comprehensive diagnostic assessment (see Principles of Practice). Level 1 Psychosocial intervention. Evidence-based psychotherapeutic interventions such
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More informationPharmacological Managment of Treatment Resistant Schizophrenia. Jean-Marie Batail - France 21 st July 2015
Pharmacological Managment of Treatment Resistant Schizophrenia Jean-Marie Batail - France 21 st July 2015 Introduction A chronic and debilitating illness - Lifetime prevalence of around 0,7%. - Beginning
More informationTherapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Prof. Dr. Christoph Hiemke Psychiatrische Klinik und Poliklinik Universität Mainz Psychopharmacotherapy Psychiatric Patient
More informationAnti-psychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study
Research Reviews: Pharmacy & Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Anti-psychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study Etwal Bou
More informationSchizophrenia and bipolar disorders are lifelong
THE STANDARD OF CARE IN TREATING PSYCHIATRIC DISORDERS Peter J. Weiden, MD,* and David G. Daniel, MD ABSTRACT In recent years, several guidelines and algorithms have appeared to help clinicians address
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationPsychopharmacological treatment of first episode psychosis
Psychopharmacological treatment of first episode psychosis Matcheri S Keshavan MD First episode Psychosis Treatment Assistance Center (FEP-TAC), Harvard Medical School, Beth Israel Deaconess Medical Center
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More informationPsychosis. Paula Gibbs, MD Department of Psychiatry University of Utah
Psychosis Paula Gibbs, MD Department of Psychiatry University of Utah Psychotic Symptoms Psychosis in a broad sense, signifies impaired reality testing ability Symptoms include: hallucinations, delusions,
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationSchizophrenia. Psychotic Disorders. Schizophrenia. Chapter 13
Schizophrenia Chapter 13 Psychotic Disorders Symptoms Alternations in perceptions, thoughts, or consciousness (delusions and hallucination) DSM-IV categories Schizophrenia Schizophreniform disorder Schizoaffective
More informationAripiprazole is available as Abilify (orodispersable) tablets (5, 10, 15, 30 mg), oral solution 1mg/ml and solution for injection 7.5 mg/ml [1].
1.1. Aripiprazole and aggravated Introduction Aripiprazole is an atypical antipsychotic drug which acts through a combination of partial agonism at dopamine D2 - and serotonin 5-HT1a receptors and antagonism
More informationLithium in bipolar disorders.
Lithium in bipolar disorders. S. Mehdi Samimi Ardestani M.D. Department of Psychiatry, Shahid Beheshti University of Medical Science, Behavioral science research center Iranian psychiatric association,
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationSuboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies
Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry, Saint Louis University,
More informationPharmacotherapy of treatment-resistant schizophrenia: a clinical perspective
Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective Markus Dold, 1 Stefan Leucht 1,2 1 Department of Psychiatry and Psychotherapy, Technical University Munich, Klinikum rechts
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationPsychotic Disorders and the use of Antipsychotic Medications: A Review
Received: 18-10-2012 Accepted: 01-11-2012 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 1 No. 11, Jan 2013 Online Available at: THE PHARMA INNOVATION Psychotic Disorders
More informationSchizoaffective Disorder
Roseanna Parkhurst-Gatewood MSN FNP-BC, PMHNP-BC DSM-5 diagnostic criteria for schizoaffective disorder 3 A. An uninterrupted period of illness during which there is a major mood episode (major depressive
More informationSchizophrenia. Psychology 372 Physiological Psychology. Overview. Characterized by. Disorganized Thoughts Hallucinations Delusions Bizarre behaviors
Overview Schizophrenia Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Probably consists of more than one disorder Is the most devastating
More informationHigh-dose antipsychotics. For patients on the brink of the neuroleptic threshold, risks of high-dose antipsychotics may outweigh any benefit.
For patients on the brink of the neuroleptic threshold, risks of high-dose antipsychotics may outweigh any benefit. Desperation or data-driven? Kamil Vojnar / Photonica Joseph M. Pierre, MD Assistant clinical
More informationThe Impact of Mental Illness on Sexual Dysfunction
Balon R (ed): Sexual Dysfunction. The Brain-Body Connection. Adv Psychosom Med. Basel, Karger, 2008, vol 29, pp 89 106 The Impact of Mental Illness on Sexual Dysfunction Zvi Zemishlany Abraham Weizman
More informationSchizophrenia and other psychotic disorders
Schizophrenia and other psychotic disorders Psychosis, schizophrenia What does psychosis mean? What does schizophrenia mean? Is there any difference between them? Psychosis, schizophrenia Psychosis: -
More informationDo Large Scale Studies of the Use of Antipsychotics Help Us Choose the Most Effective Treatments for Schizophrenia?
Do Large Scale Studies of the Use of Antipsychotics Help Us Choose the Most Effective Treatments for Schizophrenia? Mark Agius 1,2. Jesus Perez 2,3. 1. SEPT: South Essex Partnership University NHS Foundation
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationLAI Antipsychotics Frequently Asked Questions
LAI Antipsychotics Frequently Asked Questions Click each question to see the answer. Click the link to return to this list. Who should receive LAIs (long acting injectable antipsychotics)? Which antipsychotics
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationIs Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective
More informationCognitive Symptoms of Schizophrenia
Cognitive Symptoms of Schizophrenia In other information sheets we have discussed the two major types of symptoms traditionally thought to characterise schizophrenia: first of all the positive symptoms
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationSupplementary Online Content
Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:
More informationALCOHOLIC HALLUCINOSIS AND PARANOID SCHIZOPHRENIA A PARATIVE (CLINICAL AND FOLLOW UP) STUDY
Mun J. Pnckiiu. {1), 2(4), S W2 ALCOHOLIC HALLUCINOSIS AND PARANOID SCHIZOPHRENIA A PARATIVE (CLINICAL AND FOLLOW UP) STUDY COM-* G. SAMPATH* MD Y. VIKRAM KUMAR" DM* S. M. CHANNABASAVANNA* MD M.S. KESHAVAN*
More informationMethod. NeuRA Paliperidone August 2016
Introduction Second generation antipsychotics (sometimes referred to as atypical antipsychotics) are a newer class of antipsychotic medication than first generation typical antipsychotics. Second generation
More informationSchizophrenia. Delusional disorders are characterized by a persistent belief that is contrary to reality. Why do people stalk?
Schizophrenia Other psychotic disorders and causes Delusional disorders are characterized by a persistent belief that is contrary to reality. There are several subtypes recognized by the DSM IV: - - Grandiose
More informationSchizophrenia: A Lifelong Illness
Schizophrenia: A Lifelong Illness Medical Director Brain Health Exeter, NH Objectives Appreciate the historical perspectives of schizophrenia Describe our current understanding of the etiology of schizophrenia
More informationHigh Dose Antipsychotic Therapy (HDAT) guideline
Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857
More informationBehavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
More informationCHAPTER 3. Schizophrenia and Antipsychotic Treatment
CHAPTER 3 Schizophrenia and Antipsychotic Treatment What is it? It is a severe, chronic, disabling brain disease Considered to have biological origins but exact unknown 1% of population affected Schizophrenia
More informationMending the Mind: treatment of the severely mentally ill
Mending the Mind: treatment of the severely mentally ill First, the bad news Mental Illness Prevalence: putting things in perspective --More than 54 million Americans have a mental disorder in any given
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationDOWNLOAD OR READ : TREATMENT OF SCHIZOPHRENIA FAMILY ASSESSMENT AND INTERVENTION PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF SCHIZOPHRENIA FAMILY ASSESSMENT AND INTERVENTION PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of schizophrenia family assessment and intervention treatment of schizophrenia
More informationIndividualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool
Copyright John Donoghue 2015 Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool Copyright John Donoghue 2015 QUESTIONS Why do outcomes in schizophrenia remain
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationMr. E, age 37, has a 20-year history
Antipsychotics for obsessive-compulsive disorder: Weighing risks vs benefits Taylor Modesitt, PharmD, Traci Turner, PharmD, BCPP, Lindsay Honaker, DO, Todd Jamrose, DO, Elizabeth Cunningham, DO, and Christopher
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More information